Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFIGENIA: High-dose NAC in Idiopathic Pulmonary Fibrosis
NCT00639496Phase 3Completed
- Sponsor
- Zambon
- Start
- Mar 2000
- Primary completion
- Jul 2003
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing NAC Arm with Placebo Arm (2 arms). Primary endpoints: Vital Capacity at 12 months and Diffusion Capacity for Carbon Monoxide at 12 months. Started Mar 2000; status: completed.
02
Drugs
acetylcysteine
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00639496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00639496.